Where does Taysha Gene Therapies, Inc.'s cash flow data come from?

Every line is extracted from Taysha Gene Therapies, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.

	TTM Q1 '26	TTM Q4 '25	TTM Q3 '25	TTM Q2 '25	TTM Q1 '25
Net income	-$129.88M-49.7%	-$109M-22.1%	-$99.93M—	-$92.72M—	-$86.77M—
Depreciation and amortization	$1.09M-7.8%	$1.08M-12.0%	$1.09M-15.8%	$1.19M-8.1%	$1.19M-14.7%
Stock-based compensation	$15.55M+17.8%	$13.3M+1.5%	$12.99M+9.5%	$13.06M+23.9%	$13.2M+40.0%
Change in accounts payable	$213K+104%	-$153K+94.8%	$469K+118%	-$1.36M+33.6%	-$5.98M-551%
Change in other assets	——	——	——	——	$152K+103%
Other working capital changes	-$328K+55.9%	-$296K+61.9%	-$336K+61.1%	-$985K-159%	-$744K-16.3%
Change in deferred revenue	——	-$9.77M-17.3%	-$6.31M+36.4%	-$8.1M+37.1%	-$7.22M+49.0%
Non-cash operating lease expense	$1.31M+6.0%	$1.36M+11.7%	$1.26M+5.9%	$1.25M+3.9%	$1.23M+2.0%
Net cash from operating activities	-$111.95M-34.2%	-$93.09M-14.6%	-$84.68M-7.1%	-$82.13M-9.0%	-$83.45M-14.9%
Capital expenditures	$384K-37.5%	$738K+96.3%	$488K+24.2%	$415K—	$614K—
Other investing activities	——	-$134K-1,118%	-$133.75K-777%	-$76.5K—	-$15.25K—
Acquired in-process research and development	——	——	——	——	——
Net cash from investing activities	——	——	——	——	-$607K+83.3%
Proceeds from issuance of common stock	$1.66M—	$1.22M—	——	——	——
Other financing activities	-$238K—	-$337K—	——	——	——
Payment of debt issuance costs	——	——	——	——	——
Net cash from financing activities	$275.35M+258%	$274.59M+256%	$225.03M+192%	$222.83M+5.6%	$77.01M-45.4%
Net increase (decrease) in cash	$175.56M+2,477%	$196.31M+4,103%	$155.07M—	$140.02M—	-$7.39M—
Interest paid	$5.55M+5.8%	$5.4M+2.2%	$5.25M-0.3%	$5.21M+0.1%	$5.25M+1.8%
Depreciation	$1.09M-7.8%	$1.08M-12.0%	$1.09M-15.8%	$1.19M-8.1%	$1.19M-14.7%
Increase Decrease In Accrued Expense And Other Liabilities	$3.27M—	$6.29M—	——	——	——
Increase (Decrease) in Prepaid Expense and Other Assets	——	——	——	——	$152K+103%
Non Cash Change In Fair Value Of Term Loan	$608K+747%	$832K+239%	-$105K-123%	$112K-69.8%	-$94K-113%
Operating lease right-of-use asset amortization	$1.31M+6.0%	$1.36M+11.7%	$1.26M+5.9%	$1.25M+3.9%	$1.23M+2.0%
Other Noncash Income (Expense)	-$328K+55.9%	-$296K+61.9%	-$336K+61.1%	-$985K-159%	-$744K-16.3%
Payment for (Proceeds from) Other Investing Activity	——	-$134K-1,118%	-$133.75K-777%	-$76.5K—	-$15.25K—
Payments to Acquire in Process Research and Development	——	——	——	——	——
Payment Of Shelf Registration Costs	——	——	——	——	——
Proceeds From Issuance Of Common Stock Pursuant To At The Market Offering Net Of Sales Commissions And Other Offering Costs	——	$48.44M—	——	——	——
Other, net	-$238K—	-$337K—	——	——	——
Proceeds from issuance of common stock relating to employee stock plans	——	——	——	——	——
Accrued payables for capital expenditures	——	——	——	$434K+1,256%	$57.5K+130%
Fair Value Adjustment Of Warrants	——	$1.2M—	$380K—	——	——
Increase Decrease In Contract With Customer Liability	——	-$9.77M-17.3%	-$6.31M+36.4%	-$8.1M+37.1%	-$7.22M+49.0%
Proceeds From Issuance Of Warrants	——	$225K—	——	——	——
Leased assets obtained in exchange for operating lease liabilities	——	$2.37M—	——	——	——
Issuance of warrants	——	$1.64M—	——	——	——
Free cash flow	-$112.33M-33.6%	-$93.83M-15.0%	-$85.16M-7.2%	-$82.54M-9.0%	-$84.06M-15.6%
Free cash flow	-$112.33M-33.6%	-$93.83M-15.0%	-$85.16M-7.2%	-$82.54M-9.0%	-$84.06M-15.6%

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

Where does Taysha Gene Therapies, Inc.'s cash flow data come from?: Every line is extracted from Taysha Gene Therapies, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.